Celebrities + Social Media: Balancing Benefits and Risks

This article focuses on the risks and benefits of using celebrities and social media to promote pharma brands and proposes that it may be time for the pharma industry to disclose the details of payments made to celebrities as they now are required to do for physician payments.

The Debut of the Chief Patient Officer: Is It Just a Passing Fad or...

This article summarizes the roles of Chief Patient Officers in bringing the patient perspective into their company's work. Sanofi is used as a case study.

Pharma Marketing News Vol. 14, No. 3: April 2015

Welcome to Vol. 14, Issue No. 3 (APRIL 2015) of Pharma Marketing News. Patient centricity, direct-to-consumer advertising, and key opinion leaders are the focus of this issue. All are related in the sense that each area has seen major changes & shifts in thinking with more to come.

Pharma Marketing Buzzwords: The Good, the Bad, & the Just Plain Useless!

All the negative buzz about pharma buzzwords inspired the creation of the Pharma Marketing Buzzword Bingo Card (shown here) and the Pharma Marketing News 'Pharma Buzzword Survey,' which asked respondents to grade a list of buzzwords commonly heard at conferences and marketing meetings within pharmaceutical companies. This article summarizes the results of that survey.

Leveraging Multi-Channel Infographics for Patient Support: #DareTo Say SUDEP Case Study

In this article, Maureen Winigrad and John Griffith, principals at Centric Infographics, present the latest access data for two infographics campaigns spoonsored by the Epilepsy Foundation and Lunbeck Pharmaceuticals.

Patient Centricity, Transparency, & Pharma’s Reputation: Getting Beyond Lip Service

This article discusses real world examples of patient-centricity in pharmaceutical marketing and the need for more transparency in how pharmaceutical companies partner with patients online.

DTC Ad Spending Rises From the Grave: Pfizer Leads the Ghoulish Pack

This article presents the data and discusses Pfizer's leading role in the DTC ad resurgence, especially in regard to TV advertising, which accounts for almost 70% of all DTC advertising dollars.

A KOL by Any Other Name: Too Toxic for Everyday Use, or Still the...

This article summarizes the results of the KOL Name Change Survey and discusses how to change the underlying process by which pharma companies choose KOLs.

2014 Was a Good Year for FDA & Pharma: Banging Year for Drug Approvals,...

The FDA approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 201 4but sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.

The Year 2014 in Images: Pharmaguy’s Favorites from Pharma Marketing Blog

In this article, Pharmaguy presents the best images from Pharma Marketing Blog, which cover topics of importance in 2014: DTC and drug promotion spending, drug risks and adverse events, drug industry reputation, FDA and social media regulatory guidelines, mobile apps, and drug development costs.
- Advertisement -